

CMS and Incyte collaborate to develop vitiligo drug Povorcitinib in China and Southeast Asia

04 April 2024 | News

Povorcitinib is an investigational medicine being evaluated for the treatment of non-segmental vitiligo

China Medical System Holdings (CMS) and Incyte have entered into a collaboration and license agreement for the development and commercialisation of povorcitinib, a selective oral JAK1 inhibitor, to research, develop, register and commercialise the product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the Territory) and a non-exclusive license to manufacture the product in CMS' Territory.

Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS' territory.

CMS will receive an exclusive license to develop and commercialise and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.

Herve Hoppenot, Chief Executive Officer, Incyte said, "There remains a significant need for new, innovative treatment for vitiligo and other immune-mediated dermatologic conditions, and we look forward to working together with the CMS team to bringing these products to market in China."